The number of medical devices gaining approval in the US in April 2022 saw a 23% decrease when compared with March 2022, according to GlobalData’s marketed products database.
The US medical devices market was worth $169.99bn in 2021 and is expected to reach $169.71bn by 2023, according to GlobalData’s analysis.
Go deeper with GlobalData
Hospital Supplies led newly approved devices in April 2022
Looking at the device sectors, Hospital Supplies held the largest share of 20% in gaining US approval during April 2022, followed by Cardiovascular Devices with 13% and Orthopedic Devices with 11%.
As for the US medical devices market value, the Hospital Supplies market held a 14% share worth $23bn in 2021 and is expected to reach $22.97bn by 2023.
510(k) approved medical devices dominate the US market
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn April 2022, the number of new medical devices entering the US market saw a 23% decrease when compared with March 2022.
GlobalData’s database indicated that 510(k) approved medical devices entering the US market, accounted for 90% of new medical devices in April 2022, compared with 92% in the previous month.
PMA inclined by 50% in April 2022, as against 3% in March 2022. PMA have become more common during the COVID-19 pandemic, as a speedy mechanism to bring therapeutic devices to market more quickly than the usual device approval process.
Class II devices dominated the US marketing activity for new medical devices in April 2022
During April 2022, Class II medical devices entering the market accounted for 84% of new medical devices approved in April 2022, compared with 89% in March 2022. Class I devices increased from 8% of new device approvals in March 2022 to 11% in April 2022.
Cardiovascular Devices constituted the largest group of Class II devices, accounting for 12% of devices. Cardiovascular Devices topped Class III approvals at 36%. Class III devices are devices that generally pose the most risk to patients and includes implantable devices. Class I devices are of a lesser risk.
Company-developed devices lead US regulatory approvals during April 2022
Looking at the share of activity among medical device organisations, GlobalData’s database indicated that company-developed devices accounted for a 98% share of newly approved devices in the US during April 2022, while institute-developed marketed products held the remaining share.
In comparison, March 2022 saw a split of 98% in newly approved devices originating from private and public companies and 2% from institutes.
Methodology
The medical devices approval data used in this article were extracted from Medical Marketed Products Database of GlobalData’s Medical Intelligence Center. Marketed Products database covers all commercialized medical devices which are intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. Marketed products are covered from regulatory bodies like US FDA, company websites, news releases, SEC filings etc. The information is collected by following systematic research techniques and proprietary methodology.
